カテゴリ： GlobalData, アメリカ, 企業調査

Miragen Therapeutics Inc (MGEN)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Miragen Therapeutics Inc (MGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9876
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：73
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Miragen Therapeutics, Inc. (Miragen) is a clinical stage biopharmaceutical company. It discovers and develops RNA-targeted therapeutics with a focus on microRNAs and their role in diseases. The company is developing its pipeline products for the treatment of Cutaneous T-Cell Lymphoma (CTCL), Adult T-Cell Lymphoma/Leukemia, Diffuse Large-B Cell Lymphoma, Chronic Lymphocytic Leukemia, ALS, Heart Failure, Incisional Complications, Cutaneous Fibrosis, Idiopathic Pulminary Fibrosis and Other Fibrotic Indications. The pipeline development is focused on microRNA platform that regulate gene expression and influences the pathways responsible for many disease processes. Miragen is headquartered in Boulder, Colorado, the US.

Miragen Therapeutics Inc (MGEN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Miragen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
miRagen Therapeutics Raises USD8 Million in Financing 13
miRagen Therapeutics Raises USD41 Million in Series C Financing 14
miRagen Therapeutics Raises US$20 Million In Series B Financing 16
Partnerships 17
miRagen Therapeutics Enters into Agreement with Leukemia & Lymphoma Society 17
Merger 18
Signal Genetics Merges with miRagen Therapeutics 18
Licensing Agreements 20
Santaris Pharma Amends Licensing Agreement With miRagen Therapeutics 20
miRagen Therapeutics Enters Into Licensing Agreement With University of Glasgow 21
Equity Offering 22
Miragen Therapeutics Prices Public Offering of Shares for USD38.5 Million 22
Miragen Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 24
miRagen Therapeutics Raises USD40.7 Million in Private Placement of Shares 25
Debt Offering 27
miRagen Therapeutics Raises USD8.5 Million in Private Placement of Notes 27
Miragen Therapeutics Inc – Key Competitors 28
Miragen Therapeutics Inc – Key Employees 29
Miragen Therapeutics Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Nov 07, 2018: miRagen Therapeutics reports third quarter 2018 financial results and provides corporate update 31
Aug 07, 2018: miRagen Therapeutics announces second quarter 2018 financial results 33
May 09, 2018: miRagen Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 35
Mar 14, 2018: miRagen Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 37
Nov 08, 2017: miRagen Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 39
Aug 11, 2017: miRagen Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 41
May 10, 2017: miRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 43
Mar 31, 2017: miRagen Therapeutics Provides Corporate Update 45
Corporate Communications 46
Jan 05, 2018: miRagen Therapeutics Expands Board of Directors With Appointment of Arlene Morris 46
Product Approvals 47
May 24, 2017: miRagen Therapeutics Receives EU Orphan Medicinal Product Designation for MRG-106 for the Treatment of Cutaneous T-cell Lymphoma 47
Mar 31, 2017: miRagen Therapeutics Receives Orphan-Drug Designation for MRG-106 for the Treatment of Mycosis Fungoides 48
Clinical Trials 49
Jul 10, 2018: miRagen begins Phase ll trial of MRG-201 for keloid 49
May 02, 2018: miRagen Therapeutics Presents New Preclinical Data Supporting use of MicroRNA-Targeted Therapies for Ophthalmic Diseases 50
Apr 19, 2018: miRagen Therapeutics to Present Preclinical Data on MRG-201 at the Association for Research in Vision and Ophthalmology Annual Meeting 52
Mar 27, 2018: miRagen Announces Initiation of Phase 1 Clinical Trial of MRG-110 53
Feb 02, 2018: miRagen Therapeutics Presents New Data from Phase 1 Clinical Trial of MRG-106 in Mycosis Fungoides at the T-Cell Lymphoma Forum 54
Jan 24, 2018: miRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the T-Cell Lymphoma Forum 56
Dec 11, 2017: miRagen Therapeutics Presents New Interim Clinical Data Expanding on Previous Data Suggesting Positive Impact From Systemically Administered MRG-106 on Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma at 2017 American Society of Hematology Annual Meeting 57
Nov 01, 2017: miRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the 2017 American Society of Hematology Annual Meeting 59
Oct 18, 2017: miRagen Therapeutics Announces Presentations on Lead Product Candidate MRG-106 at the DIA Oligonucleotide-Based Therapeutics Conference 60
Oct 18, 2017: miRagen Therapeutics Announces Presentations on Lead Product Candidate MRG-201 at the DIA Oligonucleotide-Based Therapeutics Conference 61
Oct 13, 2017: miRagen Therapeutics Presents New Clinical Data Suggesting Positive Impact From Systemically Administered MRG-106 on Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma at EORTC Global Task Force Meeting 62
Sep 11, 2017: miRagen Therapeutics Presents New MRG-201 Preclinical Data for Inhaled MicroRNA-29 Mimic Targeting Pulmonary Fibrosis 64
Sep 01, 2017: Miragen Therapeutics to Present New MRG-201 Preclinical Inhalation Data for Pulmonary Fibrosis at the European Respiratory Society International Congress 65
Jun 08, 2017: miRagen Presents Development Update of its Clinical Product Candidate MRG-110 66
Jun 08, 2017: miRagen Therapeutics Presents Update on Development of Clinical Product Candidate MRG-201 67
Jun 08, 2017: miRagen Therapeutics to Present MRG-106 Phase 1 Clinical Trial Data at the International Conference on Malignant Lymphoma 68
Jun 05, 2017: miRagen Therapeutics Presents New Data from Phase 1 Clinical Trial Evaluating MRG-106 in Subjects with Mycosis Fungoides 69
May 17, 2017: miRagen Therapeutics to Present New Clinical Trial Data for MRG-106, an Oligonucleotide Therapeutic Targeting microRNA-155, at the American Society of Clinical Oncology Annual Meeting 70
Apr 27, 2017: miRagen Therapeutics Presents Interim Results from MRG-201 Phase 1 Clinical Trial Demonstrating Pharmacodynamic Activity in Human Skin Incisions 71
Apr 20, 2017: miRagen Therapeutics to Present MRG-201 Data at the Society for Investigative Dermatology Annual Meeting 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73

List of Tables
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Miragen Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Miragen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
miRagen Therapeutics Raises USD8 Million in Financing 13
miRagen Therapeutics Raises USD41 Million in Series C Financing 14
miRagen Therapeutics Raises US$20 Million In Series B Financing 16
miRagen Therapeutics Enters into Agreement with Leukemia & Lymphoma Society 17
Signal Genetics Merges with miRagen Therapeutics 18
Santaris Pharma Amends Licensing Agreement With miRagen Therapeutics 20
miRagen Therapeutics Enters Into Licensing Agreement With University of Glasgow 21
Miragen Therapeutics Prices Public Offering of Shares for USD38.5 Million 22
Miragen Therapeutics Plans to Raise up to USD50 Million in Public Offering of Shares 24
miRagen Therapeutics Raises USD40.7 Million in Private Placement of Shares 25
miRagen Therapeutics Raises USD8.5 Million in Private Placement of Notes 27
Miragen Therapeutics Inc, Key Competitors 28
Miragen Therapeutics Inc, Key Employees 29
Miragen Therapeutics Inc, Subsidiaries 30

List of Figures
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Miragen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Miragen Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Miragen Therapeutics Inc (MGEN)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Filtronic plc：企業の戦略・SWOT・財務分析
    Filtronic plc - Strategy, SWOT and Corporate Finance Report Summary Filtronic plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • The Mauritius Commercial Bank Limited：企業の戦略・SWOT・財務分析
    The Mauritius Commercial Bank Limited - Strategy, SWOT and Corporate Finance Report Summary The Mauritius Commercial Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • SgurrEnergy Ltd：企業の戦略的SWOT分析
    SgurrEnergy Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Change Healthcare, LLC：企業の戦略的SWOT分析
    Change Healthcare, LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Altacor Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Altacor Ltd (Altacor) is an ophthalmology company that develops and markets orphan products for chronic eye conditions. The company offers prescription and retail ophthalmology products. Its products include dry eye prescription products; dry eye retail products; products for the treatment o …
  • S. Kumars Nationwide Limited：戦略・SWOT・企業財務分析
    S. Kumars Nationwide Limited - Strategy, SWOT and Corporate Finance Report Summary S. Kumars Nationwide Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Koninklijke Philips N.V. (PHIA)：医療機器：M&Aディール及び事業提携情報
    Summary Koninklijke Philips N.V. (Philips) is a diversified technology company develops and manufactures medical systems, consumer electronics and lighting products. The company offers patient care & clinical informatics, imaging systems, healthcare transformation services and home healthcare soluti …
  • Pearson plc (PSON)：企業の財務・戦略的SWOT分析
    Pearson plc (PSON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Sudarshan Chemical Industries Ltd (SUDARSCHEM)：企業の財務・戦略的SWOT分析
    Sudarshan Chemical Industries Ltd (SUDARSCHEM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Les Laboratoires Servier：企業の戦略・SWOT・財務情報
    Les Laboratoires Servier - Strategy, SWOT and Corporate Finance Report Summary Les Laboratoires Servier - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Seacor Holdings Inc (CKH)：企業の財務・戦略的SWOT分析
    Summary Seacor Holdings Inc (Seacor) is a diversified holding company that offers domestic and international transportation, logistics and risk management consultancy services. The company offers ocean transportation and logistics services; inland transportation and logistics services; Witt O'Brien' …
  • Panalpina World Transport (Holding) Ltd.
    Panalpina World Transport (Holding) Ltd. - Strategy, SWOT and Corporate Finance Report Summary Panalpina World Transport (Holding) Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Austrian Airlines AG：企業の戦略・SWOT・財務情報
    Austrian Airlines AG - Strategy, SWOT and Corporate Finance Report Summary Austrian Airlines AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ)：製薬・医療：M&Aディール及び事業提携情報
    Summary Eckert & Ziegler Strahlen- und Medizintechnik AG (Eckert & Ziegler) is a medical device company that offers isotope technology products. The company offers radiation therapy, isotope and radio-pharma products. It provides radiation therapy products for Brachytherapy, a minimally invasive pro …
  • Corcept Therapeutics Inc (CORT)：製薬・医療：M&Aディール及び事業提携情報
    Summary Corcept Therapeutics Inc (Corcept) is a research focused pharmaceutical company which discovers, develops and commercializes innovative therapeutics in the areas of psychiatric and metabolic diseases. The company focuses on developing drugs for the treatment of severe metabolic, oncologic an …
  • Houston Methodist Hospital：企業の戦略的SWOT分析
    Houston Methodist Hospital - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Jiangsu Jiuding New Material Co Ltd (002201)：企業の財務・戦略的SWOT分析
    Jiangsu Jiuding New Material Co Ltd (002201) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stren …
  • Oglethorpe Power Corporation：電力：M&Aディール及び事業提携情報
    Summary Oglethorpe Power Corporation (Oglethorpe) is a member-owned non-profit electric utility that provides wholesale electric power to retail electric distribution cooperative members. The cooperative operates through a diverse portfolio of owned and leased power supply resources utilizing natura …
  • Kindred Healthcare Inc (KND)-製薬・医療分野：企業M&A・提携分析
    Summary Kindred Healthcare Inc (Kindred Healthcare) is a healthcare services provider with focus on post-acute care services. The company through its subsidiaries offers home health, hospice and community care services to patients in homes, nursing centers, and other residential settings. It operate …
  • MBDA Holdings SAS：企業の戦略・SWOT・財務情報
    MBDA Holdings SAS - Strategy, SWOT and Corporate Finance Report Summary MBDA Holdings SAS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆